It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Medical information request
Medical information request

GOLEMS

GOLEMS is a study that investigated the effects of 12-month fingolimod treatment on the incidence and severity of relapses, disability progression and work capability in patients with MS (N=240) in Czech Republic

Incidence of AEs and SAEs1

GOLEMS table-v
Link to article DoI
border
Abbreviations
AE, adverse event; MS, multiple sclerosis; SAE, serious AE
Reference
1. Ticha V, et al. Clin Drug Investig. 2017;37:175–186.
* Indication wording varies in different countries. The current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of fingolimod in the individual country.